Oregon Health and Science University, Portland, OR
Correspondence to: Stephen M. Smith, FRACP, FJFICM, PhD, Division of Pulmonary and Critical Care Medicine, Biomedical Research Building (UHN-67), 3181 SW Sam Jackson Park Rd, Oregon Health and Science University, Portland OR 97239-3098; e-mail: email@example.com
Vanhorebeek and colleagues1recently addressed the controversies surrounding insulin treatment of hyperglycemia in the ICU. The authors reviewed single-center studies2–3 that demonstrated benefits of tight glucose control, and a multicenter study4 that showed no improvement with insulin use. Failure to achieve glucose targets was proposed to explain the negative multicenter findings.1 This plausible hypothesis begs the question: how did the single-center and multicenter studies compare in achieving target glucose? Vanhoorebeek and colleagues1stated that 70% of treated patients in the Leuven studies2–3 had mean daily blood glucose levels < 110 mg/dL, compared with a median glucose level of 118 mg/dL in the Glucontrol study.1The Leuven studies2–3 reported 6:00 am mean glucose levels, but if the mean daily blood glucose level was calculated from these values alone, meaningful comparison of glucose control in the different studies requires the assumptions that glucose does not vary with time of day and is distributed normally. We recently determined that these two assumptions are incorrect; in our ICU, glucose levels varied in an ultradian pattern, peaking twice every 24 h, and had a positively skewed distribution.,5 These new findings complicate the comparison of the reported data undermining the conclusion that failure to achieve target glucose levels underlies the failure of the multicenter study.1
For clinicians and investigators attempting to replicate the impressive results of the Leuven studies, it is essential to know what proportion of all glucose measurements were in range for patients receiving insulin in those studies because 6:00 am values are not representative of mean daily glucose levels.5 We agree with Vanhorbeek et al1 that achieving the glucose target range is crucial when investigating the efficacy of insulin infusion protocols, but the objective comparison of these studies requires that the glucose values achieved be clearly reported and include multiple time points.
The authors have no conflicts of interest to disclose.
Become a CHEST member and receive a FREE subscription as a benefit of membership.
Individuals can purchase this article on ScienceDirect.
Individuals can purchase a subscription to the journal.
Individuals can purchase a subscription to the journal or buy individual articles.
Learn more about membership or Purchase a Full Subscription.
Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited:
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a reminder to the email address on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.